Insulet (NASDAQ:PODD – Free Report) had its price target lowered by Raymond James from $299.00 to $228.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock. Several other research analysts have also recently weighed in on the company. StockNews.com initiated coverage […]
State Board of Administration of Florida Retirement System decreased its position in Insulet Co. (NASDAQ:PODD – Free Report) by 1.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 78,435 shares of the medical instruments supplier’s stock after selling 1,440 […]
Moody National Bank Trust Division grew its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 1.8% in the second quarter, according to its most recent filing with the SEC. The firm owned 3,544 shares of the medical instruments supplier’s stock after acquiring an additional 64 shares during the quarter. Moody National Bank […]
Stephens Investment Management Group LLC trimmed its position in Insulet Co. (NASDAQ:PODD – Free Report) by 27.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,453 shares of the medical instruments supplier’s stock after selling 17,142 shares during the quarter. Stephens Investment Management Group […]
Bayesian Capital Management LP boosted its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 166.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,164 shares of the medical instruments supplier’s stock after purchasing an additional 7,600 shares […]